Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.51 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23540951 | 1.00 | FUCA1 (0.51) | FUCA1GBA1GRIN2BS1PR1S1PR5 | |
| SCHEMBL3582865 | 0.81 | FUCA1 (0.63) | FUCA1GBA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL24317322 | 0.78 | FUCA1 (0.51) | FUCA1GRIN2BS1PR1S1PR5SIGMAR1 | |
| SCHEMBL63432 | 0.76 | FUCA1 (0.58) | FUCA1GBA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL51716 | 0.76 | FUCA1 (0.58) | FUCA1GBA1S1PR1S1PR5SIGMAR1 | |
| SCHEMBL25485375 | 0.76 | ALDH1A1 (0.46) | GRIN2B | |
| SCHEMBL6621477 | 0.74 | GRIN2B (0.52) | FUCA1GBA1GRIN2BS1PR1S1PR5 | |
| SCHEMBL5640368 | 0.74 | CYP2D6 (0.65) | FUCA1GBA1GRIN2BSIGMAR1CYP2D6 | |
| SCHEMBL10642802 | 0.74 | FUCA1 (0.65) | FUCA1GBA1GRIN2BS1PR1S1PR5 | |
| SCHEMBL29201748 | 0.73 | KDM4E (0.66) | SIGMAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4217071-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4076667-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | Erasca, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2022066805-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2021127404-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203063-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | TYMS, TYMP, DHFR | FUCA1 4723/4885GBA1 1819/4885GRIN2B 356/4885 |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | DHFR, TYMS, TYMP | FUCA1 4726/4885GBA1 2132/4885GRIN2B 326/4885 |
| US-20230159563-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | KRAS, NRAS, HRAS | FUCA1 4862/4885GBA1 2939/4885GRIN2B 3613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.